 Kintara Therapeutics NASDAQ:KTRA Inc., a biopharmaceutical company focused on the development of new solid tumor cancer therapies, has revealed data from two scientific posters for its Phase 2 clinical studies of VAL-083, the companys lead compound for the treatment of glioblastoma multiforme GBM, a lethal brain cancer and other solid tumors. The data is being presented at the two-day 26th annual scientific meeting of the Society for Neuro-Oncology SNO starting on November 18, 2021, in Boston. 